Systematic review and meta-analysis: Efficacy and safety of baclofen in patients with alcohol use disorder co-morbid liver diseases.

[1]  M. Mammen,et al.  Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis. , 2022, Drug and alcohol dependence.

[2]  Luke D. Tyson,et al.  Response to 'acamprosate better than baclofen for alcohol use disorder in cirrhosis: fact or myth?' , 2022, European Journal of Gastroenterology and Hepathology.

[3]  Luke D. Tyson,et al.  Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice , 2021, European journal of gastroenterology & hepatology.

[4]  Jun Cheng,et al.  Nomogram to Predict the Survival of Chinese Patients with Alcohol-Related Liver Disease , 2021, Canadian journal of gastroenterology & hepatology.

[5]  P. Hayes,et al.  Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity , 2021, Hepatology.

[6]  Alyson K. Zalta,et al.  Self-reported PTSD symptoms and social support in U.S. military service members and veterans: a meta-analysis , 2021, European journal of psychotraumatology.

[7]  L. McGuinness,et al.  Treatment interventions to maintain abstinence from alcohol in primary care: systematic review and network meta-analysis , 2020, BMJ.

[8]  V. Shah,et al.  Provider Attitudes and Practices for Alcohol Screening, Treatment and Education in Patients with Liver Disease: a Survey from the AASLD ALD SIG. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  R. Bataller,et al.  Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting , 2019, Gut.

[10]  Shari S. Rogal,et al.  Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis , 2019, Hepatology.

[11]  P. Kamath,et al.  Alcohol‐Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study , 2019, Hepatology.

[12]  J. Samet,et al.  Alcohol Use in Patients with Chronic Liver Disease , 2018, The New England journal of medicine.

[13]  Andrew Jones,et al.  Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta‐analysis , 2018, Addiction.

[14]  W. Brink,et al.  Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis , 2018, European Neuropsychopharmacology.

[15]  T. Bschor,et al.  Baclofen for alcohol use disorder—a systematic meta‐analysis , 2018, Acta psychiatrica Scandinavica.

[16]  F. Roudot-thoraval,et al.  One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience , 2017, European journal of gastroenterology & hepatology.

[17]  M. Pirmohamed,et al.  A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic. , 2017, Alcohol.

[18]  P. Thuras,et al.  The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial , 2017, Addiction.

[19]  A. Berghold,et al.  Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. , 2017, Journal of hepatology.

[20]  A. Heinz,et al.  High-dose baclofen for the treatment of alcohol dependence (BACLAD study): A randomized, placebo-controlled trial , 2015, European Neuropsychopharmacology.

[21]  E. Krupitsky,et al.  [Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan®) for alcohol dependence]. , 2015, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[22]  B. Runyon,et al.  Utilization of baclofen in maintenance of alcohol abstinence in patients with alcohol dependence and alcoholic hepatitis with or without cirrhosis. , 2014, Alcohol and alcoholism.

[23]  A. Burt,et al.  Clinical but not histological factors predict long‐term prognosis in patients with histologically advanced non‐decompensated alcoholic liver disease , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[24]  R. Bataller,et al.  Alcoholic liver disease: pathogenesis and new therapeutic targets. , 2011, Gastroenterology.

[25]  J. Kirchner,et al.  Exposure to Trauma and Posttraumatic Stress Disorder Symptoms in Older Veterans Attending Primary Care: Comorbid Conditions and Self‐Rated Health Status , 2011, Journal of the American Geriatrics Society.

[26]  G. Bedogni,et al.  HCV, HBV and Alcohol – the Dionysos Study , 2011, Digestive Diseases.

[27]  P. Bria,et al.  Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial , 2010, Journal of psychopharmacology.

[28]  G. Bedogni,et al.  Natural Course of Chronic HCV and HBV Infection and Role of Alcohol in the General Population: The Dionysos Study , 2008, The American Journal of Gastroenterology.

[29]  G. Gasbarrini,et al.  Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study , 2007, The Lancet.

[30]  Y. Lo,et al.  Predictors of Hepatitis C Virus RNA Levels in a Prospective Cohort Study of Drug Users , 2004, Journal of acquired immune deficiency syndromes.

[31]  D. Valla,et al.  Five‐year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence , 2003, Liver international : official journal of the International Association for the Study of the Liver.

[32]  G. Gessa,et al.  Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. , 2002, Alcohol and alcoholism.

[33]  J. Larkin,et al.  Chronic ethanol consumption stimulates hepatitis B virus gene expression and replication in transgenic mice , 2001, Hepatology.

[34]  R. A. Davidoff.  Antispasticity drugs: Mechanisms of action , 1985, Annals of neurology.